IGF-1 LR3 is a recombinant, 83-amino-acid analogue of human insulin-like growth factor 1 (IGF-1), modified to bind the IGF-binding proteins far more weakly than the native molecule. Laboratory studies use it as a potent activator of the IGF-1 receptor in cell culture, notably as a growth supplement in serum-free media and in studies of proliferation, differentiation and survival signalling. Because it is a folded protein with three disulphide bonds, its quality is judged differently from that of a short synthetic peptide. This article summarises the structure, mechanism, published research and the analytical and storage standards needed for reproducible work. It offers no guidance on human use.
What is IGF-1 LR3?
IGF-1 LR3, also written IGF-1 LR3, IGF 1LR3 and Long R3 IGF-1, is classified as a recombinant analogue of human IGF-1. Native IGF-1 is a 70-residue single-chain protein of about 7.6 kDa, with three intramolecular disulphide bonds that hold its fold. Insulin-like growth factors share structural similarity with proinsulin, which is where the name originates. IGF-1 LR3 differs from the native molecule in two ways. At position 3, glutamic acid is replaced by arginine, which gives the “R3” in the name, and a 13-residue extension is added at the N-terminus, which gives the “Long”. The result is an 83-residue protein with a molecular weight of approximately 9.1 kDa, though the exact figure depends on the stated sequence and should be taken from the certificate of analysis.
The reason for the modifications lies in the biology of IGF-1 transport. In blood and in culture media containing serum, most IGF-1 is bound to a family of six IGF-binding proteins (IGFBPs), which regulate how much free growth factor can reach the receptor. The glutamic acid at position 3 and the N-terminal region are involved in binding to these proteins, and altering them reduces affinity for IGFBPs substantially while leaving receptor binding largely intact. The analogue is therefore more potent than native IGF-1 in many cell culture systems, because less of it is sequestered.
The analogue was developed in Australia by researchers at the company GroPep in the late 1980s and early 1990s, as part of work aimed at improving the performance of growth factors in industrial cell culture. It is made by recombinant expression in microbial hosts and not by chemical synthesis, since a protein of this size with correctly formed disulphide bonds is not practical to assemble by solid-phase methods.
Regulatory context matters for any UK buyer. IGF-1 LR3 is not authorised as a medicine in the United Kingdom, and IGF-1 and its analogues appear on the World Anti-Doping Agency prohibited list. A different recombinant human IGF-1 product, mecasermin, is authorised for a specific clinical indication, and it is a distinct material that is not equivalent to research-grade IGF-1 LR3. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued warnings about unlicensed products marketed for human use. IGF-1 LR3 is relevant here only as a laboratory research reagent.
Mechanism of action
IGF-1 LR3 acts through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that exists at the cell surface as a pre-formed dimer of two extracellular alpha subunits and two transmembrane beta subunits linked by disulphide bonds. Ligand binding to the alpha subunits causes a conformational change that activates the tyrosine kinase domain in the beta subunits. The receptor autophosphorylates and recruits docking proteins, principally the insulin receptor substrate (IRS) proteins and Shc.
Two main signalling cascades follow. The first is the phosphoinositide 3-kinase (PI3K) and Akt pathway, which is associated with cell survival, protein synthesis through mTOR signalling and glucose uptake. The second is the Ras, Raf and mitogen-activated protein kinase (MAPK/ERK) pathway, which is associated with proliferation and gene expression. The balance between the two depends on cell type, receptor density and the ligand’s kinetics.
Selectivity is a point to note in experimental design. IGF-1R is closely related to the insulin receptor, and the two can form hybrid receptors. IGF-1 binds the insulin receptor with much lower affinity than it binds IGF-1R, and the same is true of the LR3 analogue, but at high concentrations cross-activation can occur, and the responses should be checked with receptor-specific inhibitors or blocking antibodies.
The reduced IGFBP binding has a practical consequence. In serum-containing media, IGFBPs present in the serum will bind native IGF-1 and blunt its effect, whereas IGF-1 LR3 remains largely free. Apparent potency therefore differs between serum-free and serum-containing conditions, and the medium should always be reported. In cell-based work, “dosage” means molar or mass concentration in the medium, which depends on the protein’s measured content, its adsorption to plasticware and the accuracy of the quantification method. Proteins at low concentration stick readily to plastic, so a carrier protein is commonly added to working stocks.
What the research shows
The literature on IGF-1 is vast, and the literature specific to the LR3 analogue is much smaller. Four areas of work are summarised below in general terms. Readers should consult the primary papers for methods, concentrations and statistics, because commercial summaries often overstate findings.
The first area is the original design and characterisation of the analogue. Papers from the GroPep group in the early 1990s described analogues of IGF-1 with altered IGFBP binding and compared their activity with that of the native protein in cell-based assays. They reported that reduced binding to IGFBPs increased potency in systems where those proteins were present. The relevant literature can be located through a PubMed search on LR3IGF-I and reduced IGF-binding protein affinity.
The second area is the foundational biology of the IGF system. The somatomedin hypothesis, developed in the 1950s to 1970s, proposed that growth hormone acts partly through a liver-derived factor, later identified as IGF-1. Work by Rinderknecht and Humbel in 1978 determined the amino acid sequence of the human factor. Studies of IGF-1R, from its cloning in the 1980s to the structural work of recent years, explain how the ligand engages the receptor. These papers describe protein chemistry and receptor biology and are the basis for all later work on analogues.
The third area is the use of IGF-1 analogues in cell culture. Studies in biopharmaceutical process development have reported that replacing insulin or native IGF-1 with an IGFBP-resistant analogue supported higher cell growth and productivity in serum-free cultures of mammalian production cell lines, such as Chinese hamster ovary cells. These are bioprocessing experiments in cell culture, and they are the most widely documented practical use of the analogue. The topic can be explored through a PubMed search on IGF-1 analogue in serum-free mammalian cell culture.
The fourth area is skeletal muscle cell biology. Studies in cultured myoblasts, such as the C2C12 line, have used IGF-1 and analogues to examine proliferation, differentiation into myotubes and the Akt and mTOR signalling that regulates protein synthesis. These are cell-culture experiments, and they describe signalling readouts in the model used. They say nothing about use in any organism and should not be extended beyond the dish.
A recurring limitation runs through this body of work. Potency depends strongly on the presence of IGFBPs in the medium, results from native IGF-1 are sometimes assumed to apply to the analogue, and the activity of a recombinant protein depends on whether it is correctly folded. Reproducibility therefore depends on knowing exactly what material was used and in what medium.
Research applications
In the laboratory, IGF-1 LR3 is used in several contexts. The most common is as a growth supplement in serum-free and reduced-serum cell culture, where it replaces or supplements insulin to support the growth and viability of many cell types, particularly in bioprocessing. Because of its resistance to IGFBPs, it is used at lower concentrations than the native protein.
A second context is receptor signalling research. IGF-1R activation, IRS phosphorylation and the downstream PI3K/Akt and MAPK pathways are studied in a wide range of cell models, and IGF-1 LR3 is used as a robust agonist, often alongside receptor inhibitors, to define pathway dependence.
A third context is cell differentiation and stem cell culture. Defined media for cultured stem cells and differentiating cells frequently include IGF-1 or an analogue, and studies of differentiation protocols examine its contribution against other growth factors.
A fourth context is analytical and anti-doping science. Because IGF-1 and analogues appear on the World Anti-Doping Agency prohibited list, reference material of defined identity and purity is used to develop and validate mass spectrometry and immunoassay methods for detecting them, including methods that distinguish the analogue from the native protein by its altered mass and sequence.
Work involving animals in the United Kingdom requires institutional ethical review and authorisation under the Animals (Scientific Procedures) Act 1986. Research proteins are not authorised medicines for human or veterinary use.
Purity, storage and handling
A folded recombinant protein is assessed differently from a short synthetic peptide. The principal quality questions are whether the protein has the correct sequence and mass, whether it is correctly folded with its disulphide bonds formed, whether it is free from aggregates and truncated forms, and whether it is free from contaminants from the host organism, in particular endotoxin. Reversed-phase high-performance liquid chromatography (HPLC) with UV detection at 214 or 280 nm is the standard method for purity, and a main peak of at least 95 per cent is commonly expected. Because misfolded and oxidised species may elute close to the correct form, a shallow gradient and, where available, a second method such as size-exclusion chromatography or SDS-PAGE help to reveal aggregates and truncated products.
HPLC must be paired with mass spectrometry. The expected mass is about 9.1 kDa for the intact protein. A mass about 16 Da higher suggests methionine oxidation, a significantly lower mass suggests truncation, and a mass about 6 Da higher than expected can indicate that disulphide bonds are reduced or incorrectly formed. Because a mass spectrum cannot always show the correct disulphide connectivity, a bioassay of receptor activity in cells is the most direct test of function, and it is worth asking whether one has been performed for the batch.
A batch-specific certificate of analysis matters because purity, protein content, activity and endotoxin level vary between production runs. It should carry a lot number matching the vial, the HPLC trace or purity value, the observed and theoretical masses, the test date, the endotoxin result, the formulation and ideally an activity measurement. Lyophilised proteins can contain buffer salts and excipients, so the weighed mass is not the mass of protein, and the supplier’s stated quantity should be the measured protein content.
Because proteins of this kind aggregate, adsorb to surfaces and lose activity once in solution, batch-level verification matters more here than with short, robust peptides. UK laboratories sourcing Igf 1lr3 should expect a batch-specific certificate of analysis that states the mass found, the endotoxin level and the formulation, with lyophilised storage at -20°C, and the same documentation standard applies when weighing any best peptides supplier uk claim, since a supplier’s analytical record rather than its search ranking shows whether the vial matches its stated specification.
Lyophilised IGF-1 LR3 is generally stored at -20°C in a sealed container with desiccant, and many laboratories use -80°C for long-term archives. Vials should reach room temperature before opening so that condensation does not form on the cold powder. Reconstitution practice for growth factors differs from that for short peptides. Manufacturers commonly recommend dissolving the protein in a dilute acid, such as 10 mM acetic acid or hydrochloric acid, to a concentrated stock, then diluting into a buffer or medium containing a carrier protein such as 0.1 per cent bovine or human serum albumin to prevent loss to plastic. The stock should be divided into single-use aliquots and frozen, avoiding repeated freeze-thaw cycles, and the acceptable storage period of any dilute working solution should be validated by an activity assay and not assumed. Vigorous vortexing should be avoided, since it can promote aggregation and denaturation of a folded protein.
Light sensitivity is a secondary concern. The tyrosine, phenylalanine and methionine residues can undergo photo-oxidation, so amber vials or dark storage are advisable. Low-bind tubes help, though a carrier protein is the more effective measure for dilute solutions.
Labelling is a final indicator of quality. Clear naming that states the analogue and its length, with sequence, molecular weight, lot number, formulation, endotoxin level and an unambiguous research-only statement, suggests a supplier that understands its market. Wording that implies use in humans is a warning sign and raises regulatory concerns in the United Kingdom.
Frequently asked questions
What is IGF-1 LR3 used for in laboratory research?
It is used mainly as a potent growth supplement in serum-free cell culture and as an IGF-1 receptor agonist in signalling studies, and as a reference material in anti-doping analytical methods. It is a research reagent and not an authorised medicine in the United Kingdom.
What is the difference between IGF-1 and IGF-1 LR3?
IGF-1 LR3 is an 83-residue analogue with an arginine at position 3 and a 13-residue N-terminal extension. These changes reduce binding to IGF-binding proteins, so the analogue is more potent than the native 70-residue IGF-1 in many cell culture systems. Results from one should not be applied to the other.
How should IGF-1 LR3 be stored for research?
Keep lyophilised protein at -20°C, or -80°C for long-term archiving, in a sealed, dry, light-protected container. After reconstitution, aliquot and freeze the stock, avoid repeated freeze-thaw cycles, and use a carrier protein in dilute working solutions to limit loss to plastic.
How can I verify the quality of an IGF-1 LR3 batch?
Request a batch-specific certificate showing HPLC purity, a mass spectrometry result near 9.1 kDa, an endotoxin measurement and ideally an activity assay, with a lot number matching the vial. For critical work, independent testing by an accredited analytical laboratory confirms identity and purity.
IGF-1 LR3 is supplied for in-vitro laboratory research only and is not intended for human or veterinary use.
